AU2016214923A1 - Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers - Google Patents

Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers Download PDF

Info

Publication number
AU2016214923A1
AU2016214923A1 AU2016214923A AU2016214923A AU2016214923A1 AU 2016214923 A1 AU2016214923 A1 AU 2016214923A1 AU 2016214923 A AU2016214923 A AU 2016214923A AU 2016214923 A AU2016214923 A AU 2016214923A AU 2016214923 A1 AU2016214923 A1 AU 2016214923A1
Authority
AU
Australia
Prior art keywords
6alkyl
substituted
nr4r5
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016214923A
Other languages
English (en)
Inventor
Peter Dove
Abdelmalik Slassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of AU2016214923A1 publication Critical patent/AU2016214923A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/13—Monocyclic aromatic halogenated hydrocarbons containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016214923A 2015-02-03 2016-02-03 Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers Abandoned AU2016214923A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111240P 2015-02-03 2015-02-03
US62/111,240 2015-02-03
PCT/CA2016/050094 WO2016123706A1 (en) 2015-02-03 2016-02-03 Novel fluorinated derivatives as egfr inhibitors useful for treating cancers

Publications (1)

Publication Number Publication Date
AU2016214923A1 true AU2016214923A1 (en) 2017-08-24

Family

ID=56563262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016214923A Abandoned AU2016214923A1 (en) 2015-02-03 2016-02-03 Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers

Country Status (6)

Country Link
US (1) US20180050993A1 (enExample)
EP (1) EP3253739A4 (enExample)
JP (1) JP2018504441A (enExample)
AU (1) AU2016214923A1 (enExample)
CA (1) CA2974442A1 (enExample)
WO (1) WO2016123706A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108069913B (zh) * 2016-11-18 2022-03-01 陕西师范大学 双(吗啉基烷氧基)喹唑啉衍生物及其在抗肿瘤方面的用途
JP2020536855A (ja) * 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
WO2019071351A1 (en) * 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
CN108329276A (zh) * 2018-04-23 2018-07-27 江苏兢业制药有限公司 杂环衍生物及其制备和用途
IL281344B2 (en) 2018-09-10 2025-09-01 Mirati Therapeutics Inc Combination of adagrasib and cetuximab for cancer treatment
EP3670501A1 (en) 2018-12-17 2020-06-24 Basf Se Substituted [1,2,4]triazole compounds as fungicides
JP7474269B2 (ja) * 2019-03-15 2024-04-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP7732668B2 (ja) 2019-08-05 2025-09-02 北京志健金瑞生物医▲薬▼科技有限公司 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途
WO2021049420A1 (ja) * 2019-09-13 2021-03-18 株式会社明治 固形食品及び固形乳
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112125890B (zh) * 2020-09-25 2022-12-06 华东理工大学 一种含异吲哚酮基喹唑啉基羧酸酯类衍生物及其应用
KR20250005041A (ko) 2021-09-23 2025-01-09 에라스카, 아이엔씨. Egfr 억제제 다형체 형태

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP2280003B1 (en) * 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
ATE521603T1 (de) * 2005-02-26 2011-09-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
AU2006288716A1 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN104119351A (zh) * 2013-04-27 2014-10-29 复旦大学 4-(3-氯-4-氟苯基氨基)-7-甲氧基-喹唑啉化合物及其制备方法和用途

Also Published As

Publication number Publication date
CA2974442A1 (en) 2016-08-11
EP3253739A1 (en) 2017-12-13
EP3253739A4 (en) 2018-07-18
US20180050993A1 (en) 2018-02-22
JP2018504441A (ja) 2018-02-15
WO2016123706A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
AU2016214923A1 (en) Novel fluorinated derivatives as EGFR inhibitors useful for treating cancers
AU2017204973A1 (en) Novel fluorinated quinazoline derivatives as EGFR inhibitors
EP3037424B1 (en) Novel quinoline-substituted compound
US10696670B2 (en) Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
CN105683167B (zh) 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
JP6518690B2 (ja) （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン
WO2019046944A1 (en) INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
CN116528864A (zh) 杂芳基甲酰胺化合物
JP2017521477A (ja) ネクロトーシスを阻害するための方法
AU2019297889A1 (en) Biaryl ether-type quinazoline derivatives
CN107686477B (zh) 作为cdk4/6抑制剂的新型化合物及其应用
WO2020181386A1 (en) Fluorinated benzo[f]benzimidazol-4-9-dione ium derivatives and pharmaceutical compositions thereof and their use as survivin suppressants
TWI702205B (zh) 表皮生長因子受體抑制劑
WO2019071351A1 (en) NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
WO2018081211A1 (en) Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
EP3725777A1 (en) Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2018187187A1 (en) Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
EP4671239A1 (en) DEGRADING AGENT CONTAINING AN ARYL SUBSTITUTE FOR CDK12/13, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION AND ITS USE
CN116987073B (zh) 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用
RU2786524C2 (ru) Ингибиторы рецептора эпидермального фактора роста
WO2025003429A1 (en) Pyrazole derivatives as pd-1/pd-l1 interaction inhibitors
WO2021072028A1 (en) Activators of heme regulated inhibitor kinase (hri)

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period